Abstract:Introduction: The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients. Methods: Treatment response was defined as either continuation or discontinuation of the biologic at six months. We performed whole genome metagenomic shotgun sequencing on the baseline fecal samples to detect microbial and functional profiles. Additionally, over 1000 metabolites were captured through untargeted metabolomic profiling. Baseline diversity, dissimilarity and differential abundance analyses compared responder and non-responder groups. The prediction tool CoDaCoRe was used to identify predictive log-ratio biomarkers. We tested our identified ratios in an external cohort and attempted to replicate the microbiome-based signals of previous studies. Finally, we used a neural-network framework to model the relationship between metabolites and microbes, comparing these clusters in responders and non-responders and tested our approach with different definitions of response. Results: We identified seven metabolites to be differentially abundant between responders and non-responders (FDR < 0.05). However, no significant differences in bacterial species and pathways were detected at baseline between responders and non-responders. Our prediction analysis indicated only marginal predictive utility of the gut microbiome and fecal metabolites for treatment response, when compared to a clinical model using fecal calprotectin, disease duration and disease activity, among other factors (AUC only clinical features: 0.71±0.13, AUC microbial and clinical features: 0.73±0.12). The main predictive features of these models were the disease activity and previous anti-TNF use combined with high abundance of Phocaeicola vulgatus, Bacteroides uniformis and Alistipes onderdonkii, and the low abundance of Ruminococcus gnavus and Faecalibacterium prausnitzii. Testing our identified ratio of 10 species in an external cohort of 47 IBD patients reinforced the lack of predictive power of the microbiome. No replication of previously published predictive signals of the microbiome was observed. Additionally, we identified 2 metabolite clusters and 1 microbiome cluster associated with response, and observed that predictors were highly dependent on the definition of response. Conclusion: While previous studies of similar size have shown that microbial features can predict response to either vedolizumab (VedoNet), or vedolizumab, ustekinumab and anti-TNF, our comprehensive study found no significant differences in the gut microbiome at baseline between responders and non-responders among IBD patients treated with ustekinumab or vedolizumab. Microbial features added no predictive power to drug response in our IBD patient cohort or an independent replication cohort. Addition of metabolite features did not improve predictive power. These findings suggest minimal impact of the pre-treatment gut microbiome on treatment outcomes with these medications in IBD patients with long term chronic disease. Generalizability beyond initial study cohorts is limited, leaving predictors for individualized IBD-medication selection unidentified, but based on this work, likely do not lie in the fecal microbiome.

P803 iGenoMed-MTT: A prospective multiomic study of response to molecularly targeted therapies in IBD

P915 Multi-Omics Biomarkers for the Prediction of Response to Biologics in Patients with Inflammatory Bowel Disease

P695 Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiation

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

P852 Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s Disease

Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach

P715 Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictors

Identification of Targets for Subsequent Treatment of Crohn's Disease Patients after Failure of Anti-TNF Therapy.

DOP22 Predictive biomarkers of therapeutic response in Inflammatory Bowel Disease: a step towards personalized medicine

P192 Personalizing treatment for predicting response to infliximab in children with Crohn’s disease using proteomic biomarkers

Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study

P266 Predictive tissue-based biomarkers in treatment of Inflammatory Bowel Disease with biologicals and small molecules: a systematic review

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD study

P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease

P632 Isolation of a novel metalloproteinases transcriptional signature with robust anti-TNF therapy predictive power in patients with Ulcerative Colitis

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

P537 Analysis of immunological VAriables in ex vivo Tofacitinib-treated human biopsies from Active ulcerative colitis patients to predict clinical Response (the AVATAR study)

P1224 Predicting response to nutritional therapy in newly diagnosed children with Crohn’s Disease (CD) using multi-omics approach

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation